Sanofi and Regeneron Hit Asthma Phase III Endpoints With Dupixent
Dupixent has upped the ante on Nucala and Cinqair, showing broad activity in Phase III in asthma. But will it be bested by AstraZeneca and Amgen's tezepelumab?
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term growth. The firm is poised to file a PD-1 inhibitor with FDA in Q1.
Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.